Asset Details
Do you wish to reserve the book?
Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
Do you wish to request the book?
Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
2021
Overview
Cystic fibrosis (CF) is a genetic disease caused by mutations that impair the function of the CFTR chloride channel. The most frequent mutation, F508del, causes misfolding and premature degradation of CFTR protein. This defect can be overcome with pharmacological agents named “correctors”. So far, at least three different classes of correctors have been identified based on the additive/synergistic effects that are obtained when compounds of different classes are combined together. The development of class 2 correctors has lagged behind that of compounds belonging to the other classes. It was shown that the efficacy of the prototypical class 2 corrector, the bithiazole corr-4a, could be improved by generating conformationally-locked bithiazoles. In the present study, we investigated the effect of tricyclic pyrrolothiazoles as analogues of constrained bithiazoles. Thirty-five compounds were tested using the functional assay based on the halide-sensitive yellow fluorescent protein (HS-YFP) that measured CFTR activity. One compound, having a six atom carbocyle central ring in the tricyclic pyrrolothiazole system and bearing a pivalamide group at the thiazole moiety and a 5-chloro-2-methoxyphenyl carboxamide at the pyrrole ring, significantly increased F508del-CFTR activity. This compound could lead to the synthesis of a novel class of CFTR correctors.
Publisher
MDPI AG,MDPI
Subject
Aminoimidazole Carboxamide - chemistry
/ Benzodioxoles - pharmacology
/ CFTR
/ Chloride
/ Cystic Fibrosis - drug therapy
/ Cystic Fibrosis Transmembrane Conductance Regulator - drug effects
/ Cystic Fibrosis Transmembrane Conductance Regulator - genetics
/ Humans
/ Mutation
/ Nitrogen
/ Plasma
/ Protein Folding - drug effects
/ Proteins
